Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea
Launched by ASTRAZENECA · May 29, 2025
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a medication called tezepelumab (also known as Tezspire) for people with severe asthma in South Korea. The main goals of the study are to see how well this medication works and to understand any side effects that patients might experience while using it. The trial is not yet recruiting participants, but when it starts, it will include adults aged 18 and older who have received at least one dose of tezepelumab as prescribed by their doctor.
To be considered for this study, patients must have given their consent to participate, meaning they understand what the trial involves. However, those who are using tezepelumab for reasons not approved by health authorities or are currently involved in another clinical trial will not be eligible. Participants can expect to be monitored for their asthma symptoms and any side effects while taking the medication, helping researchers gather important information about its use in real-world settings.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients who are treated with at least one dose of tezepelumab according to the indication in the locally approved prescribing information
- • 2. Patients with evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study
- Exclusion Criteria:
- • 1. Other off-label indications according to the locally approved prescribing information
- • 2. Current participation in any interventional trial
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported